Navigation Links
DrugRisk Adds Update on Stryker Hip Recall: Claims Could Cost $190 to 390 Million
Date:3/29/2013

Chicago, IL (PRWEB) March 29, 2013

The hip implant resource center at DrugRisk.com is announcing new information on the site for patients that may have been affected by the recent Stryker hip recall. The company has informed investors they are attempting to resolve claims as patients alleging injury have requested cases be moved to a federal court.

DrugRisk was created to provide patients using popular drugs and medical devices with the latest warnings, recalls, studies and litigation news. Visitors can learn if others are experiencing similar side effects and decide if they need legal advice.

The resource center contains warnings from the British Medical Journal* and FDA** that toxic metal shavings from all-metal hips like the Stryker ABG II and Rejuvenate can cause serious conditions such as tissue damage, bone loss and damage to other organs when released into the body.

Stryker issued a recall of the Rejuvenate and ABG II modular implant systems in July of 2012***. As part of the recall, the company admitted some patients experienced adverse local tissue reactions or elevated levels of metal in the bloodstream, even if no symptoms were present***.

So far, more than 80 patients affected by the hip recall have filed Stryker lawsuits in a New Jersey multi-district court****.

DrugRisk has also learned that patients filed a petition with the U.S. Judicial Panel on Multidistrict Litigation asking that Stryker lawsuits be consolidated to a special federal court in the U.S. District Court, District of Minnesota. (In Re: Stryker Rejuvenate and ABG II Hip Implant Products Liability Litigation, Case Pending No. 20 (JPML))

Now, Stryker has advised investors that costs associated with legal claims over the hip recall may amount to between $190 and $390 million*****.

Anyone that may have been affected by the Stryker Rejuvenate or ABG II hip recall is urged to contact the DrugRisk Resource Center or speak with a lawyer about their full legal rights before signing anything from the company.

Due to the specialized nature of federal medical device injury cases, DrugRisk only recommends lawyers and law firms who have already handled Stryker recall lawsuits.

For more information on the recall, studies and litigation news related to Stryker or other metal hips, or to speak with a lawyer, visit http://www.DrugRisk.com.

*bmj.com/content/344/bmj.e1410
**fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/MetalonMetalHipImplants/ucm241604.htm
***stryker.com/en-us/products/Orthopaedics/modularneckstems/index.htm
****northjersey.com/mahwah/Over_80_lawsuits_on_hip_implants_filed_against_Mahwah-based_Stryker_Orthopaedics_.html?page=all
*****Stryker 2012 Annual Report, Other Information, Legal and Regulatory Matters, Pg. 19; http://catalog.e-digitaleditions.com/i/114936

Read the full story at http://www.prweb.com/releases/stryker-hip-lawsuit/litigation-news/prweb10581679.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisk Center Adds Latest on First of 3,000 Actos Bladder Cancer Trials
2. DrugRisks Adds New Pradaxa Study Alert As Lawsuits Increase
3. DrugRisk Update: New Pradaxa Study Questions FDA Safety Conclusion
4. DrugRisks Adds Update from First Actos Trial of Patient Alleging Bladder Cancer
5. DrugRisk Update: Evidence Submitted in Actos Lawsuit Suggests Drug Maker Knew of Cancer Risks
6. DrugRisk Update: Bayer Discloses $500 Million Remaining for Yaz Lawsuits
7. DrugRisk Pradaxa Update: Litigation Grows As New Study Adds to Risks
8. DrugRisk Pradaxa Lawsuit Update: Court Denys Boehringer’s Protective Order Request
9. DrugRisk Update: Court Allows Charges of Prior Fraud Into Pradaxa Lawsuit
10. DrugRisk Update: NuvaRing Lawsuit Trials to Begin This Year
11. DrugRisk Announces New Pradaxa Health Warning From Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... From May ... Chicago, IL, offering EarQ members the unique opportunity to learn more about Signia’s technology ... independent practice growth. , “It is our priority to see practices succeed in this ...
(Date:5/6/2016)... San Diego, CA (PRWEB) , ... May 06, 2016 , ... ... of Companies, has been family-owned and operated for over 35 years. Maintaining core values ... community has driven their success and made them a leading name in San Diego ...
(Date:5/6/2016)... , ... May 06, 2016 , ... ... and David Konur, CEO of Cardiovascular Institute of the South announced today that ... performing a live case of an Intravascular Ultrasound Guided Coronary Atherectomy. ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... overall select performance in the industry’s gold standard KLAS Performance Report, ... Epic Consulting report assessed organizations that specialize in consulting services for electronic health ...
(Date:5/5/2016)... ... May 05, 2016 , ... Florida Hospital Pepin ... atrial fibrillation (A-Fib) an alternative to long-term warfarin medication with the newly approved ... April of 2015, Florida Hospital Pepin Heart Institute doctors successfully implanted the Watchman ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... 2016  Compass Diversified Holdings (NYSE: CODI ... of leading middle market businesses, announced today its consolidated ... 2016. First Quarter 2016 Highlights , ... or "Cash Flow") of $13.6 million for the first ... $15.0 million for the first quarter of 2016; ...
(Date:5/4/2016)... ZIONA, Israel , May 4, 2016 ... BVXV) announced today that BiondVax,s CEO, Dr. Ron Babecoff ... in New York City . ... 10:30am at Pioneers 2016, a conference presented by Joseph ... Palace Hotel. The BiondVax presentation that Dr. Babecoff ...
(Date:5/4/2016)... May 4, 2016 In ... a series of free workshops across ... requirements for Good Distribution Practices (GDP). Good ... ensures that products are consistently stored, transported and handled ... (MA) or product specification. Only a few years ago, ...
Breaking Medicine Technology: